NCT06054269View on ClinicalTrials.gov

Clinical Trial to Evaluate the Immunogenicity of an Adjuvanted Influenza Vaccine Among HCP

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

192

Participants

Timeline

Start Date

November 4, 2022

Primary Completion Date

July 25, 2023

Study Completion Date

March 31, 2026

Conditions
Influenza
Interventions
BIOLOGICAL

FLUAD Quadrivalent

0.5 mL intramuscular dose of FLUAD Quadrivalent

BIOLOGICAL

FluQuadri

0.5 mL intramuscular dose of FluQuadri

Trial Locations (2)

15082

Hospital Nacional Arzobispo Loayza, Lima

15102

Hospital Nacional Cayetano Heredia, Lima

Sponsors
All Listed Sponsors
collaborator

Peruvian Clinical Research

OTHER

collaborator

Hospital Nacional Cayetano Heredia

UNKNOWN

collaborator

Hospital Nacional Arzobispo Loayza

OTHER

collaborator

U.S. Naval Medical Research Unit No.6 (NAMRU-6)

UNKNOWN

lead

Centers for Disease Control and Prevention

FED